Vanderbilt University Spasticity Management Program Evaluation Plan
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
People with severe developmental disabilities frequently have comorbidities that make
providing care to them more difficult. Spasticity is one such comorbidity. It produces
increased muscle tone that can cause stiffness in joints and bodily contortions that can
interfere with all of the major types of care provided to participants. Typically, care areas
include splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in
other functional activities. Moreover, persons with spasticity often experience pain.
Typically, spasticity is managed by health care providers using a combination of the
following therapies:
- Physical / occupational therapy (PT / OT)
- Oral medication
- Botox injections
- Intrathecal baclofen administered by the Medtronic SyncroMed pump (ITB)
- Orthopedic / neurological surgery
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
Allergan Medtronic
Treatments:
abobotulinumtoxinA Baclofen Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA